Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 16203785 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| these peptides were first screened for their ability to be recognized by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific and prostate cancer-reactive ctls from peripheral blood mononuclear cells (pbmc) of cancer patients with the hla-a11, hla-a31, and hla-a33 alleles. | |||||||
| 16203785 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| these peptides were first screened for their ability to be recognized by immunoglobulin g (igg) of prostate cancer patients and subsequently for the potential to induce peptide-specific and prostate cancer-reactive ctls from peripheral blood mononuclear cells (pbmc) of cancer patients with the hla-a11, hla-a31, and hla-a33 alleles. | |||||||
| 16203785 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| these peptides efficiently induced peptide-specific and prostate cancer-reactive ctls from pbmcs of cancer patients with the hla-a11, hla-a31, and hla-a33 alleles. | |||||||
| 16203785 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| these peptides efficiently induced peptide-specific and prostate cancer-reactive ctls from pbmcs of cancer patients with the hla-a11, hla-a31, and hla-a33 alleles. | |||||||
| 16203785 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| these peptides efficiently induced peptide-specific and prostate cancer-reactive ctls from pbmcs of cancer patients with the hla-a11, hla-a31, and hla-a33 alleles. | |||||||
| 16203785 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| antibody blocking and cold inhibition experiments revealed that the hla-a3 supertype-restricted cytotoxicity against prostate cancer cells could be ascribed to peptide-specific and cd8+ t cells. | |||||||
| 16203785 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| we identified prostate-related antigen-derived new peptide candidates for hla-a11-, hla-a31-, and hla-a33-positive prostate cancer patients. | |||||||
| 16203785 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| we identified prostate-related antigen-derived new peptide candidates for hla-a11-, hla-a31-, and hla-a33-positive prostate cancer patients. | |||||||
| 16203785 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| we identified prostate-related antigen-derived new peptide candidates for hla-a11-, hla-a31-, and hla-a33-positive prostate cancer patients. | |||||||
| 16482569 | HLA-A*02 | prostate cancer | NA | NA | NA | only_studied | |
| in a phase i clinical trial, we evaluated a vaccination with dendritic cells (dcs) loaded with a cocktail consisting of hla-a*0201-restricted peptides derived from five different prostate cancer-associated antigens [prostate-specific antigen (psa), prostate-specific membrane antigen (psma), survivin, prostein, transient receptor potential p8 (trp-p8)]. | |||||||
Copyright 2024